메뉴 건너뛰기




Volumn 20, Issue 4, 2006, Pages 556-562

Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Drug selection pressure; Mutant subclone dynamics; PML RAR mutations

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RNA;

EID: 33646479031     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404118     Document Type: Editorial
Times cited : (25)

References (35)
  • 1
    • 0027448677 scopus 로고
    • Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications
    • Warrell Jr RP. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications. Blood 1993; 82: 1949-1953.
    • (1993) Blood , vol.82 , pp. 1949-1953
    • Warrell Jr., R.P.1
  • 2
    • 0036796742 scopus 로고    scopus 로고
    • Retinoic acid resistance in acute promyelocytic leukemia
    • Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-1958.
    • (2002) Leukemia , vol.16 , pp. 1940-1958
    • Gallagher, R.E.1
  • 3
    • 0026040363 scopus 로고
    • A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
    • Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
    • (1991) Blood , vol.78 , pp. 1413-1419
    • Chen, Z.-X.1    Xue, Y.-Q.2    Zhang, R.3    Tao, R.-F.4    Xia, X.-M.5    Li, C.6
  • 4
    • 0027517243 scopus 로고
    • Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells
    • Delva L, Cornic M, Balitrand N, Guidez F, Miclea J-M, Delmer A et al. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175-2181.
    • (1993) Blood , vol.82 , pp. 2175-2181
    • Delva, L.1    Cornic, M.2    Balitrand, N.3    Guidez, F.4    Miclea, J.-M.5    Delmer, A.6
  • 5
    • 0032529284 scopus 로고    scopus 로고
    • Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
    • Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-1183.
    • (1998) Blood , vol.92 , pp. 1172-1183
    • Ding, W.1    Li, Y.P.2    Nobile, L.M.3    Grills, G.4    Carrera, I.5    Paietta, E.6
  • 6
    • 0037082488 scopus 로고    scopus 로고
    • Frequent mutations in the ligand binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo
    • Zhou D-C, Kim S, Ding W, Schulz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
    • (2002) Blood , vol.99 , pp. 1356-1363
    • Zhou, D.-C.1    Kim, S.2    Ding, W.3    Schulz, C.4    Warrell Jr., R.P.5    Gallagher, R.E.6
  • 7
    • 0032528520 scopus 로고    scopus 로고
    • Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia
    • Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A et al. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92: 374-382.
    • (1998) Blood , vol.92 , pp. 374-382
    • Imaizumi, M.1    Suzuki, H.2    Yoshinari, M.3    Sato, A.4    Saito, T.5    Sugawara, A.6
  • 8
    • 0034962358 scopus 로고    scopus 로고
    • Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia
    • Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 1998; 29: 864-872.
    • (1998) Exp Hematol , vol.29 , pp. 864-872
    • Takayama, N.1    Kizaki, M.2    Hida, T.3    Kinjo, K.4    Ikeda, Y.5
  • 10
    • 0034330993 scopus 로고    scopus 로고
    • Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
    • Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller Jr WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-3208.
    • (2000) Blood , vol.96 , pp. 3200-3208
    • Cote, S.1    Zhou, D.2    Bianchini, A.3    Nervi, C.4    Gallagher, R.E.5    Miller Jr., W.H.6
  • 11
    • 0035525766 scopus 로고    scopus 로고
    • Invitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: A novel indicator of poor patient outcome
    • Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot M-L et al. Invitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: A novel indicator of poor patient outcome. Blood 2001; 98: 2862-2864.
    • (2001) Blood , vol.98 , pp. 2862-2864
    • Cassinat, B.1    Chevret, S.2    Zassadowski, F.3    Balitrand, N.4    Guillemot, I.5    Menot, M.-L.6
  • 12
    • 0029940731 scopus 로고    scopus 로고
    • Infrequent alterations of the RARα gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines
    • Morosetti R, Grignani F, Liberatore C, Pelicci PG, Schiller GJ, Kizaki M et al. Infrequent alterations of the RARα gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines. Blood 1996; 87: 4399-4403.
    • (1996) Blood , vol.87 , pp. 4399-4403
    • Morosetti, R.1    Grignani, F.2    Liberatore, C.3    Pelicci, P.G.4    Schiller, G.J.5    Kizaki, M.6
  • 13
    • 0030992905 scopus 로고    scopus 로고
    • A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation
    • Shao W, Benedetti L, Lamph WW, Nervi C, Miller Jr WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89: 4282-4289.
    • (1997) Blood , vol.89 , pp. 4282-4289
    • Shao, W.1    Benedetti, L.2    Lamph, W.W.3    Nervi, C.4    Miller Jr., W.H.5
  • 14
    • 0030688916 scopus 로고    scopus 로고
    • Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: Differentiation induced by RA is triggered directly through PML-RARα and its down-reguation in acute promyelocytic leukemia
    • Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-reguation in acute promyelocytic leukemia. Leukemia 1997; 11: 1950-1956.
    • (1997) Leukemia , vol.11 , pp. 1950-1956
    • Kitamura, K.1    Kiyoi, H.2    Yoshida, H.3    Saito, H.4    Ohno, R.5    Naoe, T.6
  • 15
  • 16
    • 0036785378 scopus 로고    scopus 로고
    • Response to histone deacetylase inhibition of novel PML/RARalpha mutant detected in retinoic acid-resistant APL cells
    • Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C et al. Response to histone deacetylase inhibition of novel PML/RARalpha mutant detected in retinoic acid-resistant APL cells. Blood 2002; 100: 261-270.
    • (2002) Blood , vol.100 , pp. 261-270
    • Cote, S.1    Rosenauer, A.2    Bianchini, A.3    Seiter, K.4    Vandewiele, J.5    Nervi, C.6
  • 18
    • 0038446666 scopus 로고    scopus 로고
    • Quantitative real-time RT-PCR analysis of PML-RARα mRNA in adult acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129
    • Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S et al. Quantitative real-time RT-PCR analysis of PML-RARα mRNA in adult acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
    • (2003) Blood , vol.101 , pp. 2521-2528
    • Gallagher, R.E.1    Yeap, B.Y.2    Bi, W.3    Livak, K.J.4    Beaubier, N.5    Rao, S.6
  • 19
    • 0035189081 scopus 로고    scopus 로고
    • Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription-PCR
    • Slack JL, Bi WB, Livak KJ, Beaubier N, Yu M, Clark M et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription-PCR. J Mol Diagnost 2001; 3: 141-149.
    • (2001) J Mol Diagnost , vol.3 , pp. 141-149
    • Slack, J.L.1    Bi, W.B.2    Livak, K.J.3    Beaubier, N.4    Yu, M.5    Clark, M.6
  • 20
    • 0030812198 scopus 로고    scopus 로고
    • Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
    • Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D et al. Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 1997; 90: 1656-1663.
    • (1997) Blood , vol.90 , pp. 1656-1663
    • Gallagher, R.E.1    Willman, C.L.2    Slack, J.L.3    Andersen, J.W.4    Li, Y.P.5    Viswanatha, D.6
  • 21
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3    Gorre, M.E.4    Paquette, R.L.5    Kuriyan, J.6
  • 22
    • 0036682481 scopus 로고    scopus 로고
    • Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
    • Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai J-L, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-1018.
    • (2002) Blood , vol.100 , pp. 1014-1018
    • Roche-Lestienne, C.1    Soenen-Cornu, V.2    Grardel-Duflos, N.3    Lai, J.-L.4    Philippe, N.5    Facon, T.6
  • 23
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis
    • Branson S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood 2003; 102: 276-283.
    • (2003) Blood , vol.102 , pp. 276-283
    • Branson, S.1    Rudzki, Z.2    Walsh, S.3    Parkinson, I.4    Grigg, A.5    Szer, J.6
  • 24
    • 0030061520 scopus 로고    scopus 로고
    • Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse
    • Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61-66.
    • (1996) Leukemia , vol.10 , pp. 61-66
    • Grimwade, D.1    Howe, K.2    Langabeer, S.3    Burnett, A.4    Goldstone, A.5    Solomon, E.6
  • 25
    • 0035525767 scopus 로고    scopus 로고
    • Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia
    • Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell Jr RP, Miller Jr WH. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
    • (2001) Blood , vol.98 , pp. 2651-2656
    • Jurcic, J.G.1    Nimer, S.D.2    Scheinberg, D.A.3    DeBlasio, T.4    Warrell Jr., R.P.5    Miller Jr., W.H.6
  • 26
    • 24744443720 scopus 로고    scopus 로고
    • High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy
    • Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niedersieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
    • (2005) Blood , vol.106 , pp. 2128-2137
    • Willis, S.G.1    Lange, T.2    Demehri, S.3    Otto, S.4    Crossman, L.5    Niedersieser, D.6
  • 28
    • 18244405576 scopus 로고    scopus 로고
    • The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage
    • Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 2005; 105: 3686-3690.
    • (2005) Blood , vol.105 , pp. 3686-3690
    • Salomoni, P.1    Bernardi, R.2    Bergmann, S.3    Changou, A.4    Tuttle, S.5    Pandolfi, P.P.6
  • 29
    • 0038527642 scopus 로고    scopus 로고
    • Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
    • Di Croce L, Raker VA, Corsaro M, Faxi F, Fanelli M, Faretta M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
    • (2002) Science , vol.295 , pp. 1079-1082
    • Di Croce, L.1    Raker, V.A.2    Corsaro, M.3    Faxi, F.4    Fanelli, M.5    Faretta, M.6
  • 30
    • 17044401059 scopus 로고    scopus 로고
    • Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia
    • Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019-3025.
    • (2005) Blood , vol.105 , pp. 3019-3025
    • Sanz, M.A.1    Tallman, M.S.2    Lo-Coco, F.3
  • 31
    • 4644293319 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    • Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.
    • (2004) Blood , vol.104 , pp. 1995-1999
    • Lo-Coco, F.1    Cimino, G.2    Breccia, M.3    Noguera, N.I.4    Diverio, D.5    Finolezzi, E.6
  • 32
    • 0035145435 scopus 로고    scopus 로고
    • All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
    • Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
    • (2001) Semin Hematol , vol.38 , pp. 13-25
    • Fenaux, P.1    Chomienne, C.2    Degos, L.3
  • 34
    • 22144443475 scopus 로고    scopus 로고
    • Drug resistance in cancer: Principles of emergence and prevention
    • Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714-9719.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 9714-9719
    • Komarova, N.L.1    Wodarz, D.2
  • 35
    • 21744437143 scopus 로고    scopus 로고
    • Predicting the effect of transcription therapy in hematologic malignancies
    • Melnick A. Predicting the effect of transcription therapy in hematologic malignancies. Leukemia 2005; 19: 1109-1117.
    • (2005) Leukemia , vol.19 , pp. 1109-1117
    • Melnick, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.